NeurologyLive

12/19/2025

In our latest Q&A, Walter Kernan, MD, of Yale University School of Medicine, discussed the latest primary prevention guidelines and their focus on lifelong brain health and risk factor management. Kernan outlined some of the most notable takeaways, including using the American Heart Association's “Life’s Essential 8” as a foundation for reducing stroke risk, while stressing the importance of regular access to primary care.

In addition, Kernan underscored a lifespan approach to brain health, with early and repeated risk factor assessment, and detailed specific clinical considerations. He also identified major evidence gaps that warrant further research, including maternal stroke, sleep health, obesity, and health system–level primary care delivery.

Read More: https://hubs.li/Q03YCMYJ0

12/19/2025

Today is the day! We're extremely excited to announce the launch of Frontlines with Frontera, a clinician-led podcast by Jennifer Frontera, MD, providing in-depth conversations around neurocritical care, stroke, and complex bedside decision-making🧠🏥

Tune into episode 1, featuring Sahar Zafar, MD, MBBS, which covers the expanding role of AI in neurocritical care, use of EEG-based AI models, and future applications of AI for seizure prophylaxis, among other topics.

Listen in: https://hubs.li/Q03YCs_q0

12/18/2025

Innovative care models are reshaping access to cardiac genetic counseling 🧬

At NSGC 2025, Emily Brown, MGC, CGC (Johns Hopkins Hospital) highlighted how cardiogenetics clinics are using telehealth, testing-first workflows, genetic counselor–only clinics, and educational webinars to reduce wait times and reach underserved patients—without adding staff.

This session underscored practical, scalable solutions to address inequities in access to cardiovascular genetic testing and counseling.

🎥 Watch time: 3 minutes
👉 https://hubs.li/Q03YwJPS0

At NSGC 2025, the genetic counselor at Johns Hopkins Hospital discussed how cardiac genetics clinics are adopting alternative care models to increase access to genetic testing and counseling. [WATCH TIME: 3 minutes]

12/18/2025

What’s new in Alzheimer disease research❓

At , experts shared important updates on clinical trials, biomarkers, and future treatment strategies. In a recent NeuroVoices interview, Alzheimer’s specialist Dr. Alireza Atri breaks down what these findings mean— including results from the EVOKE trials studying oral semaglutide in early Alzheimer 📑

While some results were disappointing, the conversation also highlighted promising advances in amyloid therapies, blood-based biomarkers, and prevention strategies that may shape future care ⚕️

Read more: https://hubs.li/Q03Yt1kD0

The director of the Banner Sun Health Research Institute discussed a variety of meaningful Alzheimer disease research presented at the 2024 Clinical Trials on Alzheimer's Disease Conference (CTAD).

12/18/2025

: The U.S. Food and Drug Administration has approved the expanded indication for Johnson & Johnson's n‐butyl cyanoacrylate (Trufill) liquid embolic system for embolization of the middle meningeal artery (MMA) in patients with symptomatic subacute and chronic subdural hematoma, as an adjunct treatment to surgery.

Read More:

The expanded indication brings n-butyl cyanoacrylate’s established performance into the treatment of chronic subdural hematoma, a condition for which traditional surgical interventions may not always be suitable or effective.

12/18/2025

Did you know that many adults with epilepsy have never had genetic testing—even though their condition may be genetic? 🧬

A new group called GEAN (Genetic Epilepsy in Adults Network) is working to change that. Led by epilepsy specialists across North America and supported by the American Epilepsy Society, GEAN aims to expand genetic testing for adults with epilepsy and better understand what these conditions look like across adulthood 🧓

Neurologist Elizabeth Gerard, MD explains how this effort could improve diagnosis, guide treatment, and help patients and families better understand the future.

Read more: https://hubs.li/Q03YsLfV0

Elizabeth Gerard, MD, an epileptologist at Northwestern Medicine, provided clinical insights on a new consortium, GEAN, which aims to expand genetic testing and define adult phenotypes for rare genetic epilepsies across North America.

12/18/2025

🧠🤖 How might social robots and embodied AI reshape neurologic care?

Emerging evidence suggests that embodied AI companions—such as social robots used in dementia care—may reduce agitation, depression, and loneliness while improving quality of life. Unlike disembodied voice assistants, these systems engage affective and multisensory neural pathways, offering unique benefits for patients with Alzheimer disease, , and Parkinson disease.

As adoption grows, neurologists are being called to lead on ethical deployment, transparency, and rigorous clinical evaluation. This article explores where social robotics fits into neurology today—and what evidence is still needed to move the field forward.

Read more 👉 https://hubs.li/Q03Yk4Fn0

Neal K. Shah talked about how social robots could support emotional well-being in patients with neurologic conditions by reducing loneliness and promoting engagement in health-related activities.

12/18/2025

🎙️ Now Streaming: Mind Moments podcast

In this episode, Sneha Mantri, MD, MS, chief medical officer at the Parkinson's Foundation, explores key questions clinicians face when managing mood and behavior symptoms in Parkinson disease, including:

• When mood symptoms may signal early disease
• How screening tools fit into busy clinical workflows
• The role of integrated mental health care
• Ongoing barriers to access and mental health parity

Full episode here:

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sneha Mantri, MD, MS. [LISTEN TIME: 24 minutes]

12/17/2025

Over the last several decades, treatment for generalized myasthenia gravis (gMG) has shifted to more targeted treatments that may help improve symptoms with potentially fewer side effects and not as broad an impact on the immune system. Learn more: bit.ly/4qylDb0

by Johnson & Johnson

12/17/2025

🩺 New Stroke Prevention Guidance: The updated 2024 AHA/ASA primary prevention guideline replaced the 2014 recommendations, offering evidence-based strategies to reduce stroke risk across the lifespan.

In a conversation with NeurologyLive, study author Walter Kernan, MD, provided some quick-hitting facts about these guidelines, as well as their clinical implications.

View:

Walter Kernan, MD, senior research scientist at Yale University, discussed the latest primary stroke prevention guidelines and their focus on lifelong brain health and risk factor management.

12/17/2025

🔥 AES 2025 Spotlight: Updated phase 2 and open-label extension data for azetukalner demonstrate durable, progressive seizure reduction in focal onset seizures—extending out to 7 years in some patients.

NeurologyLive sat down with Christopher Kenney, MD, FAAN, to discuss mechanism, long-term efficacy, safety signals, and what’s next for the phase 3 FOS program. He also previewed parallel development in primary generalized tonic-clonic seizures.

Christopher Kenney, MD, FAAN, chief medical officer at Xenon Pharmaceuticals, reviews encouraging long-term data behind azetukalner, a first-in-class Kv7 channel opener, as a potential treatment for focal onset seizures.